235 related articles for article (PubMed ID: 23673444)
41. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
[TBL] [Abstract][Full Text] [Related]
42. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
[TBL] [Abstract][Full Text] [Related]
43. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
44. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy.
Levine AM; Tulpule A; Quinn DI; Gorospe G; Smith DL; Hornor L; Boswell WD; Espina BM; Groshen SG; Masood R; Gill PS
J Clin Oncol; 2006 Apr; 24(11):1712-9. PubMed ID: 16520466
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of aflibercept in the treatment of metastatic colorectal cancer.
Macarulla T; Sauri T; Tabernero J
Expert Opin Biol Ther; 2014 Oct; 14(10):1493-505. PubMed ID: 25152076
[TBL] [Abstract][Full Text] [Related]
46. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
[TBL] [Abstract][Full Text] [Related]
47. Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program.
Chen R; Li J; Hu WW; Wang ML; Zou SL; Miao LY
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1111-23. PubMed ID: 24061864
[TBL] [Abstract][Full Text] [Related]
48. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
49. Anti-angiogenic activity of melatonin in advanced cancer patients.
Lissoni P; Rovelli F; Malugani F; Bucovec R; Conti A; Maestroni GJ
Neuro Endocrinol Lett; 2001; 22(1):45-7. PubMed ID: 11335879
[TBL] [Abstract][Full Text] [Related]
50. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
51. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
52. Ziv-aflibercept: binding to more than VEGF-A--does more matter?
Clarke JM; Hurwitz HI
Nat Rev Clin Oncol; 2013 Jan; 10(1):10-1. PubMed ID: 23149898
[TBL] [Abstract][Full Text] [Related]
53. [Are antiangiogenic antibodies universal for solid tumor?].
Ray-Coquard I; Bachelot T; Saba C; Confavreux C; Brantus JF; Rustam F; Ghesquière H; Sebban C; Biron P; Guastalla JP; Blay JY
Bull Cancer; 2007 Jul; 94 Spec No():S191-6. PubMed ID: 17846004
[TBL] [Abstract][Full Text] [Related]
54. Clinical pharmacokinetics of bevacizumab in patients with solid tumors.
Lu JF; Bruno R; Eppler S; Novotny W; Lum B; Gaudreault J
Cancer Chemother Pharmacol; 2008 Oct; 62(5):779-86. PubMed ID: 18205003
[TBL] [Abstract][Full Text] [Related]
55. A novel LC-MS/MS approach to the pharmacokinetic study of free and bound aflibercept simultaneously.
Kong L; Liu F; Huo L; Sha C; Liu W; Yu F
Anal Bioanal Chem; 2020 Feb; 412(4):1003-1010. PubMed ID: 31897562
[TBL] [Abstract][Full Text] [Related]
56. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.
Yang J; Wang X; Fuh G; Yu L; Wakshull E; Khosraviani M; Day ES; Demeule B; Liu J; Shire SJ; Ferrara N; Yadav S
Mol Pharm; 2014 Oct; 11(10):3421-30. PubMed ID: 25162961
[TBL] [Abstract][Full Text] [Related]
57. Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.
Sörenson S; Fohlin H; Lindgren A; Lindskog M; Bergman B; Sederholm C; Ek L; Lamberg K; Clinchy B
Eur J Cancer; 2013 Jan; 49(1):115-20. PubMed ID: 22951014
[TBL] [Abstract][Full Text] [Related]
58. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Subramanian J; Morgensztern D; Govindan R
Clin Lung Cancer; 2010 Sep; 11(5):311-9. PubMed ID: 20837456
[TBL] [Abstract][Full Text] [Related]
59. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
[TBL] [Abstract][Full Text] [Related]
60. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
